AN2 Therapeutics | Developing Therapies for Rare, Chronic, and …
At AN2 Therapeutics our mission is to develop therapeutics to treat rare, chronic, and serious infectious disease in areas of high unmet medical need. Developing novel therapies using our boron chemistry platform
Leadership | Board of Directors | Partners | AN2 Therapeutics
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from our boron chemistry platform. We have a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases ...
Development Pipeline - AN2 Therapeutics
AN2 has a pipeline of novel boron-based compounds that have the potential to be best in class therapeutics. The company intends to advance its global health initiatives using non-dilutive funding, which the company obtains from sources such as …
Investor Relations | AN2 Therapeutics, Inc
Oct 17, 2024 · AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases ...
Latest News | Media Contact - AN2 Therapeutics
Nov 21, 2019 · Latest News for AN2 Therapeutics, developing therapeutics to treat rare, chronic, and serious infectious disease in areas of high unmet medical need.
Technology | Boron Drug Discovery Platform | AN2 Therapeutics
Pioneering work at Anacor Pharmaceuticals led to the generation of a class of boron compounds known as fused boron heterocyclic compounds that demonstrated greatly improved drug-like properties. We believe our drug discovery approach is uniquely suited to address the challenges of infectious disease.
Careers | Job Opportunities - AN2 Therapeutics
Join Our Team! At AN2 Therapeutics you’ll find an experienced group of exceptional individuals that share a passion for addressing the challenges of infectious diseases and oncology and improving global human health.
AN2 Therapeutics Closed $80 Million Series B Financing
Jan 7, 2022 · AN2 successfully completed an oversubscribed $80 million Series B redeemable convertible preferred stock financing in March 2021. The financing is expected to support advancement of AN2’s development candidate epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung ...
AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
Feb 10, 2022 · The Phase 1b double-blind, placebo-controlled, dose-ranging study was designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of oral epetraborole administered to healthy volunteers at doses ranging from 250 mg to 1,000 mg for 28 days.
Oct 20, 2022 · AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Boron chemistry platform is driving a pipeline of anti-infectives. Epetraborole is late-stage compound for NTM lung disease. QIDP, Fast Track, and Orphan Drug designations granted in U.S.